文献速递神经肿瘤

间变性脑膜瘤中CDKN2A拷贝数状态评估的陷阱

Pitfalls in the evaluation of CDKN2A copy number status in meningioma.
PubMed 文献 · J Neurooncol · 2025-04-14

该研究分析9例间变性脑膜瘤中DNA甲基化谱、分子倒置探针分析、靶向二代测序和荧光原位杂交等分子方法与p16、MTAP蛋白表达的一致性,发现3例纯合CDKN2A缺失病例仍表达MTAP蛋白,MTAP基因呈半合子缺失,且FISH探针可产生误导性结果。作者认为MTAP免疫组化不能作为CDKN2A缺失的唯一替代标志物。

要点

  • p16缺失与分子检测一致性较好,但3例纯合CDKN2A缺失者MTAP蛋白仍表达,MTAP基因呈半合子缺失。
  • 涵盖两基因的FISH探针可产生误导性结果。
  • 作者认为MTAP免疫组化不能单独用于间变性脑膜瘤CDKN2A缺失评估,p16/MTAP免疫组化阴性时应行分子检测。

核心结论

  • 作者认为MTAP免疫组化作为间变性脑膜瘤CDKN2A缺失的唯一替代标志物不可靠。
  • 作者认为高分辨率染色体微阵列定量拷贝数分析可精确判定CDKN2A缺失。
  • 作者结论:高级别脑膜瘤p16/MTAP免疫组化阴性应促使行CDKN2A缺失的分子分析,且不应仅依赖MTAP免疫组化进行分级。

研究设计与样本

  • 研究分析9例间变性脑膜瘤中DNA甲基化谱、分子倒置探针分析、靶向二代测序和荧光原位杂交等分子方法与p16、MTAP蛋白表达的一致性。

主要发现

  • p16缺失与分子方法相关性良好。
  • 3例纯合CDKN2A缺失病例中MTAP蛋白仍表达,且这3例MTAP基因呈半合子缺失。
  • 涵盖两基因的FISH探针产生误导性结果。

临床怎么用

  • 作者结论:高级别脑膜瘤p16/MTAP免疫组化阴性应促使行CDKN2A缺失的分子分析。
  • 作者结论:不应仅依赖MTAP免疫组化进行间变性脑膜瘤分类。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Meningiomas are the most common primary intracranial tumors, with anaplastic variants linked to a poor prognosis. CDKN2A deletions are key markers of malignancy and were integrated into the 2021 WHO classification for anaplastic meningiomas. Both p16 and MTAP immunohistochemistry (IHC) are employed to assess CDKN2A loss, though each marker has limitations in accuracy to varying degrees. METHODS: This study analyzed the concordance between molecular methods - DNA methylation profiling, molecular inversion probe (MIP) analysis, targeted next-generation sequencing (NGS), and fluorescence in situ hybridization (FISH) - and protein expression of p16 and MTAP in nine anaplastic meningiomas. RESULTS: We showed that while p16 loss correlated well, MTAP protein was still expressed in three cases despite homozygous CDKN2A deletions. In those three cases the MTAP gene was hemizygously deleted. Additionally, a FISH probe encompassing both genes generated misleading results. CONCLUSION: Our results suggest that MTAP IHC can be unreliable as a sole surrogate for CDKN2A loss in anaplastic meningioma. Quantitative copy-number analysis via high-resolution chromosomal arrays enables precise determination of CDKN2A deletions. Given the therapeutic implications of WHO grading, accurate molecular testing is critical. We conclude that negative p16/MTAP IHC in high-grade meningiomas should prompt molecular analysis for CDKN2A deletions, and MTAP IHC should not be solely relied upon for classification.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Zschernack V, Pinto G, Friker LL, et al. Pitfalls in the evaluation of CDKN2A copy number status in meningioma. J Neurooncol. 2025. PMID: 40227557. doi:10.1007/s11060-025-05029-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。